Funda Meric-Bernstam, MD, discusses fam-trastuzumab deruxtecan-nxki and the evaluation of the agent in the phase 2 DESTINY-PanTumor02 trial.
Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center, discusses fam-trastuzumab deruxtecan-nxki (Enhertu) and the evaluation of the agent in the phase 2 DESTINY-PanTumor02 trial (NCT04482309).
Currently, trastuzumab deruxtecan is the standard of care for patients withHER2-low breast cancer, HER2-positive breast cancer, HER2-positive gastric cancer, and HER2-mutant lung cancer.
The open-label, multicenter, phase 2 DESTINY-PanTumor02 study assessed trastuzumab deruxtecan, a potent antibody-drug conjugate in patients with advanced solid tumors who were not eligible for curative therapy. In the study, treatment with trastuzumab deruxtecan was administered at a dose of 5.4 mg/kg every 3 weeks across all cohorts.
Eligibility for enrollment in the DESTINY-PanTumor02 trial was open to patients in their second- or later-line of therapy, who have a HER2 expression by immunohistochemistry of 3+ or 2+, and an ECOG performance status of 1 or 0.
0:10 | Trastuzumab deruxtecan is already known to be active as an antibody drug conjugate and we already know that it has efficacy in the setting of HER2-low, as well as HER2-positive breast cancer, in HER2-positive gastric cancer, as well as in HER2-mutant lung cancer. Here, our question was, we know that HER2 is expressed in other tumor types, so can we assess whether trastuzumab deruxtecan would have antitumor activity?
0:41 | We asked this question by enrolling patients that had advanced solid tumors. We enrolled patients that had HER2-expression that was either 3+ or 2+ using immunohistochemistry. Patients were enrolled either with a central test or local test. If the local test was used for enrollment, we did central tests for confirmation. We enrolled 6 different tumor types, and we also enrolled all tumors in other tumor baskets that allowed for patients that had diseases other than those that we enrolled, as well as those that had breast cancer, gastric, gastric cancer, colon cancer,and lung cancer.